NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE198958 Query DataSets for GSE198958
Status Public on May 01, 2022
Title A circulating risk score, based on combination of exo-miR130a-3p and fibrinopeptide A, as predictive biomarker of relapse in early stage non-small cell lung cancer patients [miRNA]
Organism Homo sapiens
Experiment type Non-coding RNA profiling by array
Summary To date, the 5-year overall survival of early stage non-small cell lung cancer (NSCLC) is still unsatisfactory at 59.8%. Therefore, reliable prognostic factors are needed. Growing evidence shows that cancer progression may depend on a double interconnection between cancer cells and the surrounding tumor microenvironment, and circulating molecules may represent promising markers of cancer recurrence. Here, we performed in-depth analysis of circolome-derived markers, including Exo-miRnome and peptidome in 67 radically resected NSCLCs, to identify a prognostic score. The miRnome profile selected exo-miR130a-3p as the most overexpressed in patients with relapse. Peptidome analysis identified 4 fibrinopeptide A (fpA), which were depleted in progressing patients. Notably, the combination of exo-miR130a-3p and the greatest fpA (2-16) built a score where high-risk patients had 24 months of disease-free survival. Moreover, in vitro transfections showed that higher levels of exo-miR-130a-3p lead to a deregulation of some pathways involved in metastasis, in angiogenesis, such as in coagulation. In conclusion, the identified risk score integrating circulating markers can help clinicians predict early-stage NSCLC patients who are more likely to relapse after initial surgery.
 
Overall design A total of 67 resected NSCLC samples were analyzed to define a miRNA signature capable to predict patients who experience progression of the disease (PD).
 
Contributor(s) Coco S, Longo L, Rossi G, Chiorino G, Guana F, Ostano P
Citation(s) 35884472
Submission date Mar 18, 2022
Last update date Aug 01, 2022
Contact name simona coco
E-mail(s) simona.coco@hsanmartino.it, coco.simona@gmail.com
Phone +390105558316
Organization name IRCCS Ospedale Policlinico San Martino
Lab Lung Cancer Unit
Street address L.go R. Benzi, 10
City Genova
ZIP/Postal code 16132
Country Italy
 
Platforms (1)
GPL21576 Agilent-070156 Human_miRNA_V21.0_Microarray 046064 (Probe Name version)
Samples (67)
GSM5961661 NSCLC Plasma_Exo-miRNA_rep 1 [800132]
GSM5961662 NSCLC Plasma_Exo-miRNA_rep 1 [800138]
GSM5961663 NSCLC Plasma_Exo-miRNA_rep 1 [800160]
This SubSeries is part of SuperSeries:
GSE198959 A circulating risk score, based on combination of exo-miR130a-3p and fibrinopeptide A, as predictive biomarker of relapse in early stage non-small cell lung cancer patients
Relations
BioProject PRJNA817572

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE198958_RAW.tar 184.6 Mb (http)(custom) TAR (of TXT)
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap
External link. Please review our privacy policy.